# Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

> **NCT00862836** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT00862836
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862836, "Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00862836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*